Table 2 Nodal stage for N2-3M0(Any T) breast cancers by receptor-based subtype, SEER 17 registries, 2010–2021

From: Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021

 

HR+/HER2− (N = 28,585)

HR+/HER2+ (N = 6223)

TNBC (N = 5785)

HR−/HER2+ (N = 2767)

 

N

%

N

%

N

%

N

%

N2a

16,920

59.2

3353

53.9

2727

47.1

1225

44.3

N2b

211

0.7

73

1.2

143

2.5

55

2.0

N2NOS*

1356

4.7

509

8.2

432

7.5

235

8.5

N3a

7656

26.8

1473

23.7

1417

24.5

730

26.4

N3b

1489

5.2

419

6.7

549

9.5

259

9.4

N3c

526

1.8

260

4.2

348

6.0

180

6.5

N3NOS*

427

1.5

136

2.2

169

2.9

83

3.0

  1. HER2 human epidermal growth factor receptor-2, HR hormone receptor, TNBC Triple negative breast cancer.
  2. *Not used during 2018–2021.
Back to article page